Archive

Posts Tagged ‘leprae’

A Common Genetic Fingerprint in Leprosy and Crohn’s Disease?

December 17th, 2009 2 comments

Researchers into the relationship between Mycobacterium avium subsp. paratuberculosis and Crohn’s Disease have for years been stating that the most appropriate infectious model for Crohn’s Disease is a comparison with Leprosy. Therefore, it comes as no surprise that there is now growing genetic evidence that they are correct, as described in an editorial in the New England Journal of medicine, reproduced below.

Causation of Crohn’s disease by Mycobacterium avium subspecies paratuberculosis
Hermon-Taylor J
Can J Gastroenterol. 2000 Jun;14(6):521-39.

Is Crohn’s disease caused by a mycobacterium? Comparisons with leprosy, tuberculosis, and Johne’s disease
Greenstein RJ
Lancet Infect Dis. 2003 Aug;3(8):507-14.




Title: A Common Genetic Fingerprint in Leprosy and Crohn’s Disease?
Authors: Erwin Schurr, Ph.D. and Philippe Gros, Ph.D.
Source: New England Journal of Medicine: Editorial: December 16, 2009

The cause-and-effect relationship between severe infections and death suggests that microbial pathogens are evolutionary sculptors of the genome. However, the genetic component of susceptibility to infections in the general population is complex and heterogeneous and is modulated by environmental factors such as determinants of microbial virulence. Thus, it is a challenge to identify specific genetic effects in human populations. Availability of the human genome sequence, combined with knowledge of genetic variation, has facilitated the genomewide association study, a powerful approach to detecting genetic associations. In this issue of the Journal, Zhang and colleagues1 describe a genomewide association study of leprosy, a bacterial disease.

Leprosy manifests with a broad pathologic spectrum. At one end is the localized paucibacillary form, characterized by a small number of hypopigmented, anesthetic skin lesions; at the other end is the disseminated multibacillary form, involving numerous skin lesions with a high bacillary load. Paucibacillary infection is associated with immune responses mediated by type 1 helper T (Th1) cells (involving the production of interferon-γ and interleukin-2) that promote granuloma formation and limit bacterial replication and dissemination. The multibacillary form, in contrast, is associated with the Th1 polarization of the immune response (and the production of interleukin-4 and interleukin-10), which promotes uncontrolled bacterial replication and more severe pathology.

Population studies and studies of twins have established that there is a genetic component to susceptibility to leprosy.2,3 Linkage and association studies have implicated variants of the HLA-DR region, PARK2 (encoding parkin), LTA (encoding lymphotoxin alpha), and chromosome 10p13 in conferring susceptibility to leprosy in independent populations.3

Zhang and colleagues describe the results of genomewide scanning in persons with paucibacillary or multibacillary forms of leprosy from eastern or southern China. The authors compared the prevalence of each genetic marker — in this case, each single-nucleotide polymorphism (SNP), which is currently the marker typically used in genomewide association studies — in 706 case patients and 1225 unaffected persons. A total of 93 SNPs were shown to have a significant association with leprosy. These SNPs were then tested in three replication sets of more than 3000 patients and nearly 6000 controls from eastern or southern China. The data implicate CCDC12 (the gene encoding coiled-coil domain containing 122), C13orf31 (encoding chromosome 13 open reading frame 31), NOD2 (encoding nucleotide-binding oligomerization domain containing 2), TNFSF15 (encoding tumor necrosis factor [ligand] superfamily member 15), RIP2K (encoding receptor-interacting serine–threonine kinase 2), and the HLA-DR–DQ locus. Several of the proteins encoded by these genes are involved in microbial sensing and in the early innate immune and inflammatory responses. NOD2 recognizes a component of the mycobacterial wall, and stimulation of NOD2 results in the recruitment of RIPK2 and indirectly prompts the activation of the transcriptional regulator nuclear factor κB (NF-ΚB)4 — which in turn activates the transcription of genes encoding proinflammatory cytokines including TNFSF15. On the surface of phagocytes, HLA-DR molecules present bacterial antigens to CD4+ T cells to initiate Th1-cell polarization.

Human genetic studies have implicated both IL12B (the gene encoding interleukin-12β) and NOD2 in increased susceptibility to mycobacterial disease, and mouse mutants lacking either Nod2, Ripk2, or Infg (encoding interferon-γ) are highly susceptible to tuberculosis.5,6,7 The fact that such genes are now implicated through a genomewide association study of leprosy not only validates this approach to studying the disease, but also raises interest in the newly implicated genes (e.g., CCDC12 and C13orf31), the functions of which are not known.

Another interesting aspect of the study is that variation in some of the implicated genes is known to be associated with bowel inflammatory conditions. A frame-shift mutation in NOD2 has been identified as a strong susceptibility factor for Crohn’s disease; additional NOD2 mutations have been discovered not only in persons with Crohn’s disease but also in those with Blau’s syndrome and in those with early-onset sarcoidosis.8 Likewise, variants of TNFSF15 and IL12B have been associated with Crohn’s disease.9 These findings are consistent with studies of mouse models that have also established a role for Nod2, Ripk2, and Nfkb in intestinal homeostasis and colitis.10,11 Together, these studies establish a strong genetic and functional link between susceptibility to leprosy and predisposition to Crohn’s disease.

Although the results described by Zhang and colleagues are exciting, additional experiments are required to validate and refine their conclusions. Genomewide association studies are fairly crude. For example, a regulatory SNP in the LTA gene, previously identified as a leprosy risk factor,12 was not tested in the platform used by Zhang and colleagues. Moreover, linkage disequilibrium (a state in which genetic markers — typically those in close physical proximity — are more likely than not to be inherited together) can extend over large intervals, with the main genetic effect located within a region that is a considerable distance from the SNPs showing the disease association. As known SNPs increase in number, the dissection of local effects of linkage disequilibrium will become more accurate, and testing for the presence of associations in groups of persons of differing ancestries will shed light on the extent to which these findings of Zhang and colleagues apply to other populations.

How do we move from P values to understanding pathogenesis and response to infection and, finally, to clinical outcomes? Although genomewide association studies rarely identify causative genetic lesions, they do point to specific genes and biologic pathways that can be targeted for pharmacologic intervention, irrespective of the mechanism underlying genetic susceptibility. A particularly attractive aspect of the study by Zhang and colleagues is the apparently narrow focus of the genetic control, which highlights early antigen sensing and signaling in the pathogenesis of both leprosy and Crohn’s disease. It is tempting to speculate that these common genetic signatures support, albeit indirectly, the proposal that a proportion of Crohn’s disease cases may have a mycobacterial cause.13,14 Irrespective of its strength, such a link may broaden the therapeutic treatment options for both diseases.

In comparison with the study by Zhang and colleagues, genomewide association studies of susceptibility to malaria15 and to infection with the human immunodeficiency virus16 suggest that the contribution of common genetic variants is more limited. Why would this be so? The genomic variability of Mycobacterium leprae isolates is very small, and M. leprae has undergone substantial reductive evolution, possibly through adaptation to its human host. This may suggest that larger host genetic effects in infectious disease reflect decreased pathogen variability. In this view, pathogens with greater genetic variability, such as M. tuberculosis, will give rise to a more complex genetic architecture of host susceptibility.

Is M. avium subspecies paratuberculosis (MAP) the cause of multiple “autoimmune” and “inflammatory” diseases in man? Inferences from the anti-MAP activity of methotrexate, 6-MP, 5-ASA and thalidomide, on MAP in culture.

December 16th, 2007 Comments off

Another piece of research which establishes the anti-paratuberculosis antibiotic activity of molecules which are currently thought to have an immuno-suppressant effect in Crohn’s Disease.

http://www.paratuberculosis.org/pubs/proc9/abst185f_o4.htm

=======================================
BACKGROUND:

We have shown that the “immuno-modulators” methotrexate and 6-MP and the “anti-inflammatory” 5-ASA inhibit MAP growth (www.PLoSONE.org) and concluded that their most plausible mechanism of action in several idiopathic diseases is as antiMAP antibiotics. Thalidomide is an “immunomodulator” used in multiple “auto-immune” and “inflammatory” diseases and the mycobacterial diseases leprosy and tuberculosis. We now test the hypothesis that thalidomide inhibits MAP growth.

METHODS

Thalidomide (+-) and (+) and (-) and its two components, phthalimide and 1-hydroxy 2,6 piperidine dione (HPD) were evaluated in culture of two strains each of MAP (ATCC 19698 [bovine] & Dominic [human]) and M. avium subspecies avium (ATCC 25291 & 101.) We used a radiometric (14CO2 Bactec(R)) detection system. Inhibition is indicated by “percent decrease in cumulative Growth Index” (%-DcGI) from control.

RESULTS:

Phthalimide has no dose dependent inhibition on any strain. There was no dose dependent inhibition on either M. avium strain with thalidomide or its components. With the two MAP strains, there is dose dependent inhibition with thalidomide (+1); Dominic (31%-DcGI) and ATCC 19698 (26%-DcGI) at 64microg/ml. Thalidomide (+) is more inhibitory than (-). HPD is, on a weight for weight basis, the most inhibitory agent evaluated; Dominic (46%-DcGI) and ATCC 19698 (44%-DcGI at 64microg/ml)

CONCLUSIONS:

We show in vitro heretofore-undescribed inhibition of MAP growth by racaemic thalidomide. Thalidomide (+) is more potent than (-). Of thalidomide’s two moieties, phthalimide has no antiMAP activity and HPD is the active component in inhibiting MAP growth. We suggest that since 1942, initially with 5-ASA, the medical profession has unknowingly been treating MAP infections. These data are compatible with our concern that MAP is zoonotic. We conclude that all idiopathic “autoimmune” and “inflammatory” diseases, empirically treated with medications that we show are active against MAP, should now be evaluated for MAP as the etiological agent.

Crohn’s Disease, Leprosy and Thalidomide

May 25th, 2006 Comments off

Leprosy is caused a member of genus Mycobacteria, M. leprae, and some forms of leprosy are treated by “tamping down the immune system” with anti-TNF agents, such as thalidomide. Steroids are also used for the treatment of leprosy[1].

FDA approves Thalidomide for Hansen’s disease side effect, imposes unprecedented restrictions on distribution.
http://www.fda.gov/bbs/topics/ANSWERS/ANS00887.html

Redeeming thalidomide
http://pubs.acs.org/hotartcl/mdd/00/jun/mddkling.html

Remicade’s anti-TNF activity might also be useful for leprosy (a known mycobacterial disease), but there haven’t been any trials of remicade/infliximab for Leprosy (Hansen’s Disease), presumably because the manufacturers know that the average third-world leper can’t afford $30K+ a year to be maintained on remicade, and thus won’t spend the huge money necessary for the relevant clinical trials.

But Thalidomide, the poor man’s anti-TNF drug, is long out of patent, and is cheap, and so gets used for the poor lepers. But there is a fightback in the leprosy medical community, primarily because of the nasty birth defects that Thalidomide causes.

No Role for Thalidomide in Leprosy
http://www.paho.org/English/AD/DPC/CD/thalidomide.htm

Thalidomide has been trialled for Crohn’s Disease.

Thalidomide reduces tumour necrosis factor {alpha} and interleukin 12 production in patients with chronic active Crohn’s disease
http://gut.bmjjournals.com/cgi/content/abstract/50/2/196

Thalidomide: New uses for notorious drug
http://www.mayoclinic.com/health/thalidomide/HQ01507

So the relative success of treatment of Crohn’s Disease with Remicade is NOT an argument against a mycobacterial cause. In fact, if the Crohn’s Disease to Leprosy analogy that has been made by some researchers[2,3] is true, then Remicade treatment in Crohn’s could be an argument FOR a mycobacterial cause.

1. Steroid prophylaxis for prevention of nerve function impairment in leprosy: randomised placebo controlled trial.
http://bmj.bmjjournals.com/cgi/content/abstract/328/7454/1459

2. Comparisons with leprosy, tuberculosis and Johne’s disease: is Crohn’s disease caused by a mycobacterium?
http://www.paratuberculosis.org/proc7/abst6_p6.htm

3. Mycobacterium avium subspecies paratuberculosis in the causation of Crohn’s disease
http://www.wjgnet.com/1007-9327/6/630.asp

Genome sequence of Mycobacterium avium subspecies paratuberculosis (MAP) complete.

November 30th, 2002 Comments off

Researchers at the University of Minnesota, in conjunction with researchers from the United States Department of Agriculture, have completed their work on the sequencing of the genome of MAP. Their press release can be found here

http://www.johnes.org/handouts/files/UM_news_release.pdf

The availability of a new wealth of information about MAP, and its relationship with other closely-related disease-causing mycobacteria, including

Mycobacterium leprae
http://www.pasteur.fr/actu/presse/press/leprosy.html

Mycobacterium tuberculosis
http://genolist.pasteur.fr/TubercuList/
http://www.sanger.ac.uk/Projects/M_tuberculosis/

Mycobacterium bovis
http://www.sanger.ac.uk/Projects/M_bovis/

Mycobacterium marinum
http://www.sanger.ac.uk/Projects/M_marinum/

will hopefully begin the vitally important process of developing new diagnostics for detecting MAP infection in humans, and developing a deeper understanding of the relationship between such infection and Crohn’s Disease.

We can further hope that knowledge from the Tuberculosis and Leprosy research fields will enrich the spectrum of anti-MAP treatments currently available.

Mycobacteria and Sarcoidosis?

August 26th, 1998 Comments off

Check out the abstracts below about Sarcoidosis, Mycobacterium avium and Mycobacterium paratuberculosis. Paratuberculosis is a subspecies of avium, i.e. it’s fulll classification is “Mycobacterium avium subspecies paratuberculosis”.

And of course, for a wealth of information about paratuberculosis and Crohn’s, visit

http://crohn.ie/archive/welcome.htm

__________________________________________________________________
Title
Identification of Mycobacterium avium complex in sarcoidosis.

Author
el-Zaatari FA; Naser SA; Markesich DC; Kalter DC; Engstand L; Graham DY
Address Inflammatory Bowel Disease Laboratory, Veterans Affairs Medical
Center, Houston, Texas 77030, USA.

Source
J Clin Microbiol, 34(9):2240-5 1996 Sep

Abstract
Cell wall-defective bacteria which later reverted to acid-fast bacilli have been isolated from sarcoid tissue. These have not been conclusively shown to be mycobacteria. Specific PCR assays were applied to identify mycobacterial nucleic acids in these cultured isolates and in fresh specimens obtained from patients with sarcoidosis. Positive amplification and hybridization were observed with Mycobacterium avium complex- and/or Mycobacterium paratuberculosis-specific probes in five of the six cultured isolates and two fresh skin biopsy samples and one cerebrospinal fluid specimen. There was no amplification or hybridization with Mycobacterium tuberculosis or M. avium subsp. silvaticum probes, respectively. Patients’ sera were also tested for antibody reactivities by immunoblotting with M. paratuberculosis recombinant clones expressing the 36,000-molecular-weight antigen (36K antigen) (p36) and the 65K heat shock protein (PTB65K). All seven sarcoidosis, four of six tuberculosis, and all six leprosy patient serum specimens showed strong reactivity with p36 antigen. In contrast, 13 of 38 controls showed only weak reactivity with p36 (P = 0.002 for controls versus sarcoidosis samples). Similarly, PTB65K reacted with high intensity with sera from 5 of 5 sarcoidosis, 5 of 6 tuberculosis, and 5 of 6 leprosy patients, compared with its low-intensity reaction with 5 of 22 controls (P = 0.001 for controls versus sarcoidosis samples). This study demonstrates the isolation and/or identification of M. paratuberculosis or a closely related M. avium complex strain from sarcoid skin lesions and cerebrospinal fluid. Furthermore, the reactivity of antibodies in sarcoid patient sera against p36 and PTB65K antigens was comparable to the reactivity of sera obtained from patients with known mycobacterial disease. Collectively, these data provide further support for the theory of the mycobacterial etiology of sarcoidosis.

____________________________________________________________________
Title
Serologic reactivity against Mycobacterium paratuberculosis antigens in patients with sarcoidosis.

Author
Reid JD; Chiodini RJ
Address
Robinson Memorial Hospital, Ravenna, Ohio.

Source
Sarcoidosis, 10(1):32-5 1993 Mar

Abstract
Although sarcoidosis has clinical and histopathologic similarities to some forms of tuberculosis and other mycobacterial infections, attempts to establish a mycobacterial etiology have not been successful. Using cytoplasmic antigens derived from a wild strain of Mycobacterium paratuberculosis in an enzyme-linked immunosorbent assay, patients with sarcoidosis were found to have immunoglobulin levels significantly higher than those found in a control population in the IgG, but not in IgA or IgM antibody classes. Results were comparable to those reported from patients with Crohn’s disease, where M. paratuberculosis has been intensively studied as a possible etiologic agent. To elucidate these relationships, examination of DNA from sarcoid tissues for possible homology with DNA from M. paratuberculosis and closely related organisms, as well as cultural attempts with techniques and media appropriate for M. paratuberculosis may be warranted.

__________________________________________________________________